Bibliografia complementaria

Al-Tarawneh, S.K., Border, M.B., Dibble, C.F., and Bencharit, S. (2011). Defining salivary biomarkers using mass spectrometry-based proteomics: a systematic review. OMICS 15, 353-361.

Bantscheff, M. (2012). Mass spectrometry-based chemoproteomic approaches. Methods Mol Biol 803, 3-13.

Bantscheff, M., and Drewes, G. (2012). Chemoproteomic approaches to drug target identification and drug profiling. Bioorg Med Chem 20, 1973-1978.

Bantscheff, M., and Drewes, G. (2012). Chemoproteomic approaches to drug target identification and drug profiling. Bioorg Med Chem 20, 1973-1978.

Barrett, J., Brophy, P.M., and Hamilton, J.V. (2005). Analysing proteomic data. Int J Parasitol 35, 543-553.

Bischoff, R., and Schlüter, H. (2012). Amino acids: Chemistry, functionality and selected non-enzymatic post-translational modifications. J Proteomics 75, 2275-2296.

 Castagnola, M., Cabras, T., Vitali, A., Sanna, M.T., and Messana, I. (2011). Biotechnological implications of the salivary proteome. Trends Biotechnol 29, 409-418.

Chandramouli, K., and Qian, P.Y. (2009). Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics 2009.

Hu, S., Loo, J.A., and Wong, D.T. (2007). Human saliva proteome analysis. Ann N Y Acad Sci 1098, 323-329.

Knudsen, G.M., and Chalkley, R.J. (2011). The effect of using an inappropriate protein database for proteomic data analysis. PLoS One 6, e20873.

Lee, J.M., Han, J.J., Altwerger, G., and Kohn, E.C. (2011). Proteomics and biomarkers in clinical trials for drug development. J Proteomics 74, 2632-2641.

Liebler, D.C. (2002). Introduction to proteomics : tools for the new biology (Totowa, NJ: Humana Press).

Li, L., Bum-Erdene, K., Baenziger, P.H., Rosen, J.J., Hemmert, J.R., Nellis, J.A., Pierce, M.E., and Meroueh, S.O. (2010). BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome. Nucleic Acids Res 38, D765-773.

Ohtsuki, S. (2012). Pharmacoproteomic approach by quantitative targeted proteomics. Yakugaku Zasshi 132, 479-487.

Rosenberg, I.M. (1996). Protein analysis and purification : benchtop techniques (Boston: Birkhäuser).

 Pan, S., Chen, R., Aebersold, R., and Brentnall, T.A. (2011). Mass spectrometry based glycoproteomics--from a proteomics perspective. Mol Cell Proteomics 10, R110.003251.

Pandey A, M.M. (2000). Proteomics to study genes and genomes. Nature 405, 837-846.

Patterson SD, A.R. (2003). Proteomics: the first decade and beyond. Nature Genetics 33.

Simpson, R.J. (2003). Proteins and proteomics : a laboratory manual (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).

Sund, J., Alenius, H., Vippola, M., Savolainen, K., and Puustinen, A. (2011). Proteomic characterization of engineered nanomaterial-protein interactions in relation to surface reactivity. ACS Nano 5, 4300-4309.

Westermeier, R., and Naven, T. (2002). Proteomics in practice : a laboratory manual of proteome analysis (Weinheim: Wiley-VCH).

Wilkins, M.R., Appel, R.D., Van Eyk, J.E., Chung, M.C., Gorg, A., Hecker, M., Huber, L.A., Langen, H., Link, A.J., Paik, Y.K., et al. (2006). Guidelines for the next 10 years of proteomics. Proteomics 6, 4-8.

 

Chapal N, M.L., Molina F, Laplanche M, Pau B, Petit P. (2004). Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam Clin Pharmacol 18, 413-422.

Doyle, S. (2011). Fungal proteomics: from identification to function. FEMS Microbiol Lett 321, 1-9.